Stockscreener 앱 받기
2.335
11.55%
-0.305
시간 외 거래:
2.34
0.005
+0.21%
전일 마감가:
$2.64
열려 있는:
$2.53
하루 거래량:
542.94K
Relative Volume:
1.14
시가총액:
$77.51M
수익:
-
순이익/손실:
$-86.60M
주가수익비율:
-0.8244
EPS:
-2.8324
순현금흐름:
$-67.37M
1주 성능:
-43.05%
1개월 성능:
-6.60%
6개월 성능:
-73.04%
1년 성능:
-82.20%
1일 변동 폭
$2.2668
$2.68
1주일 범위
$2.2668
$3.90
52주 변동 폭
$2.2668
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
명칭
Lexeo Therapeutics Inc
전화
(212) 547-9879
주소
345 PARK AVENUE SOUTH, NEW YORK
LXEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
2.335 | 77.51M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2024-06-06 | 개시 | H.C. Wainwright | Buy |
| 2023-11-28 | 개시 | Chardan Capital Markets | Buy |
| 2023-11-28 | 개시 | JP Morgan | Overweight |
| 2023-11-28 | 개시 | Leerink Partners | Outperform |
| 2023-11-28 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-28 | 개시 | Stifel | Buy |
모두보기
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Lexeo stock hits 52-week low at $2.31 amid sharp annual decline - Investing.com India
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Raised by Bank of New York Mellon Corp - Defense World
What is Chardan Capital’s Estimate for LXEO FY2025 Earnings? - Defense World
Q1 EPS Estimate for Lexeo Therapeutics Increased by Analyst - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $18.00 at Leerink Partners - MarketBeat
HC Wainwright Reaffirms Buy Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
What is Leerink Partnrs’ Forecast for LXEO FY2025 Earnings? - Defense World
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw? - MSN
Analysts Offer Predictions for LXEO Q1 Earnings - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $20.00 at Royal Bank of Canada - Defense World
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
H.C. Wainwright maintains Buy on Lexeo stock, $23 target By Investing.com - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's - Asianet Newsable
Pharma Frenzy: Volatility Ignites Biotech Sector - Sharewise
Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? - MSN
RBC Cuts Price Target on Lexeo Therapeutics to $20 From $24, Keeps Outperform, Speculative Risk - MarketScreener
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Cut to $18.00 by Analysts at Leerink Partners - Defense World
Lexeo Therapeutics Advances Genetic Medicine Initiatives - TipRanks
10 Small Firms Kick Off Monday with Strong Gains - Insider Monkey
Leerink cuts Lexeo Therapeutics price target to $18, maintains Outperform By Investing.com - Investing.com Canada
Lexeo Therapeutics stock soars 40% on positive trial data By Investing.com - Investing.com South Africa
Lexeo Therapeutics stock soars 40% on positive trial data - Investing.com India
Lexeo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - MarketScreener
SEC Form 424B5 filed by Lexeo Therapeutics Inc. - Quantisnow
Lexeo Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $75 MillionSEC Filing - Marketscreener.com
Lexeo Therapeutics, Inc. (LXEO) reports earnings - Quartz
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - The Manila Times
Insider Stock Buyers At Lexeo Therapeutics Recouped Some Losses This Week - simplywall.st
Lexeo Therapeutics (NASDAQ:LXEO) & Monte Rosa Therapeutics (NASDAQ:GLUE) Critical Survey - Defense World
LEXEO THERAPEUTICS Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Purchases 4,127 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World
Lexeo Therapeutics (LXEO) to Release Quarterly Earnings on Monday - Defense World
Lexeo stock hits 52-week low at $4.23 amid market challenges - MSN
Lexeo stock plunges to 52-week low at $3.42 amid market challenges By Investing.com - Investing.com South Africa
Lexeo stock plunges to 52-week low at $3.42 amid market challenges - Investing.com India
Lexeo Therapeutics chief medical officer sells $10,410 in stock By Investing.com - Investing.com South Africa
Lexeo Therapeutics CEO sells $19,090 in stock By Investing.com - Investing.com Nigeria
Top Executives at Lexeo Therapeutics Cash In on Stock Sales! - TipRanks
Lexeo Therapeutics chief development officer sells shares worth $6,557 - Investing.com
Lexeo Therapeutics CEO sells $19,090 in stock - Investing.com India
Lexeo Therapeutics chief medical officer sells $10,410 in stock - Investing.com India
Lexeo Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Lexeo Therapeutics CMO Sells Shares to Cover Tax Obligations - TradingView
Lexeo Therapeutics Inc (LXEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):